After signing up, you'll start to receive regular news updates from us.
BioTrove Launches Next-Generation Mass Spectrometry System
Complete the form below to unlock access to ALL audio articles.
BioTrove, Inc. has announced launch of its second-generation RapidFire Mass Spectrometry system. Capable of fully-automated, unattended operation for up to eight hours, during which a total of ten 384-well microtiter plates can be analyzed, the enhanced system was developed in collaboration with a major U.S. pharmaceutical company that funded the project in order to receive accelerated delivery of the first instrument.
“Research is a 24-7 effort. Our customers expressed urgent need for walk-away automation and the ability to run the system for extended periods without staff support in order to improve research speed and efficiency,” said Can Ozbal, Ph.D., General Manager of RapidFire Products.
“The new RapidFire system makes that possible, thanks to close collaboration with our customers–something we’ve embraced since installing the first RapidFire Mass Spectrometry system three years ago. This next-generation instrument results from our tireless commitment to supporting customers’ work,” he added.
The next-generation instrument incorporates new hardware and software features to streamline non-primary screening applications–including kinetic experiments, supporting structure-activity relationship studies through the determination of IC50 values and mechanism of inhibition studies, along with in vitro ADME experiments–in which data quality is of the utmost importance. A number of improvements to minimize sample-to-sample carryover and to maximize sensitivity have also been incorporated into the new RapidFire system.
“Eight of the top 12 U.S. pharmaceutical companies now use RapidFire to advance drug discovery, lead optimization and pipeline development efforts, and our dialogue with these industry leaders enables us to hear first-hand which features and applications are important to big pharma,” said Al Luderer, Ph.D., president and CEO of BioTrove. “The next-generation RapidFire system shows the power of collaboration with outcomes-oriented preclinical laboratories, and resulted in the instrument they desired.”
